MedTrace Logo

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

NCT05520892 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 580

Last updated 2024-05-16

No results posted yet for this study

Summary

To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia, and to reduce related adverse reactions and economic burdens on the premise of ensuring the remission rate

Conditions

  • Newly Diagnosed Immune Thrombocytopenia in Children, First Line Treatment

Interventions

DRUG

intravenous immunoglobulin

To compare the efficacy of two different dosage regimens of intravenous immune globulin (IVIG) in the treatment of children with newly diagnosed immune thrombocytopenia

Sponsors & Collaborators

  • The First Affiliated Hospital of Xiamen University

    collaborator OTHER

  • Zhangzhou Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Quanzhou First Hospital

    collaborator OTHER

  • Nanping First Hospital Affiliated to Fujian Medical University

    collaborator UNKNOWN

  • The Second Hospital of Anhui Medical University

    collaborator OTHER

  • The Affiliated Hospital Of Guizhou Medical University

    collaborator OTHER

  • Longyan City First Hospital

    collaborator OTHER

  • The Affiliated Hospital of Putian University

    collaborator OTHER

  • Fujian Medical University Union Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
29 Days
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2025-08-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520892 on ClinicalTrials.gov